BioNTech SE: Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine

Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4/5-adapted bivalent vaccines will be available in the

Related Keywords

Germany ,United States ,Canada ,United Kingdom ,Sylke Maas ,Fosun Pharma ,Linkedin ,Genentech ,Twitter ,Pfizer Inc Nasdaq ,European Commission ,Drug Administration ,International Coalition Of Medicines Regulatory Authorities ,Exchange Commission ,Pfizer ,European Union ,European Medicines Agency ,Facebook ,Roche Group ,International Coalition ,Medicines Regulatory Authorities ,Emergency Use Authorization ,Marketing Authorization Holder ,Product Characteristics ,Package Leaflet ,Breakthroughs That Change Patient ,Pfizer News ,Annual Report ,Looking Information ,Factors That May Affect Future ,New Technologies ,Private Securities Litigation Reform Act ,Vaccine Advisory ,Technical Committees ,Quarterly Report ,Biontech ,Omplete ,Submission ,European ,Medicines ,Agency ,Micron ,Adapted ,Bivalent ,Vaccine ,